Product Launch

Phytopharm PLC
24 April 2006


Company Contact:                                U.K. Investor Relations                           
Phytopharm plc                                  Contact:
Dr Richard Dixey                                Financial Dynamics                                                
[phone]                                 David Yates / Ben Atwell
Dr Daryl Rees                                   [phone]
[phone]
www.phytopharm.com


                           Launch of Phytopica(TM)

  Phytopharm responsible for manufacture and Schering-Plough Animal Health for
                         marketing and distribution

GODMANCHESTER, Cambridgeshire, U.K. (24 April 2006) - Phytopharm plc (LSE: PYM;
NASDAQBB: PHYOF; PHYOY) ('Phytopharm') announces today the UK launch by
Schering-Plough Animal Health (Schering-Plough) of Phytopica(TM), a unique 3
plant extract that offers an effective aid to the management of canine atopic
dermatitis.

In January 2006, Phytopharm entered into an exclusive global marketing and
distribution agreement with Schering-Plough for Phytopica(TM).Under the terms of
the agreement, Phytopharm is responsible for the manufacture and sale of
Phytopica(TM)to Schering-Plough.  Schering-Plough is responsible for the global
sales, marketing and distribution of Phytopica(TM).

Phytopica(TM)has been proven extensively in clinical trials and enjoys strong
support from veterinary dermatologists in the UK.  Launched at the world's
largest companion animal congress, the British Small Animal Veterinary
Association (BSAVA) in Birmingham, April 20-23, Phytopica(TM)has an excellent
safety profile and is recognised as suitable for all dogs whatever size or
breed.  Following the UK launch, Schering-Plough will seek to market and
distribute Phytopica(TM)in Europe and the USA.

Phytopica(TM)is a wholly natural product combining the beneficial effects of 3
plants and provides a novel 3 in 1 approach to help maintain a normal healthy
immune system, support normal white cell function and provide anti-oxidant
benefits.

Commenting on today's announcement, Richard Dixey, Chief Executive Officer of
Phytopharm, said:

'We are delighted with the launch of Phytopica(TM)by one of the world's leading
animal health companies.  Phytopica(TM)has already had firm support from
veterinary dermatologists, and with Schering-Plough's global presence we look
forward to strong growth.'

Commenting on today's announcement, Sarah Jane Minter, Marketing Manager at
Schering Plough Animal Health, said:

'We are looking forward to maximizing the potential of this unique 3 plant
extract that offers a convenient, cost effective aid to the management of canine
atopic dermatitis.'


                                     -ENDS-

NOTES TO EDITORS

Canine dermatological disorders are well recognised by veterinarians to be a
major problem in small animal practice, with an estimated 15% of the UK dog
population (equating to around 900,000 dogs) affected by skin conditions due to
allergy (Muller & Kirk's Small Animal Dermatology, 6th Ed, 2000).


Phytopharm plc

Phytopharm is focused on the research and development of novel pharmaceutical
and functional food products based on clinical and pre-clinical data generated
from medicinal plant extracts.  The Company has seven development programmes in
four disease areas: neurodegeneration, obesity and metabolic disease,
dermatology and inflammation and has a portfolio of two marketed veterinary
products.

More information concerning Phytopharm's activities can be found on its web site
at

                           http://www.phytopharm.com

This press release may contain forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S.
Securities Exchange Act of 1934 with respect to the financial condition, results
and business achievements/performance of Phytopharm and certain of the plans and
objectives of its management.  These statements are statements that are not
historical facts.  Words such as 'should', 'expects', 'anticipates',
'estimates',  'believes' or similar expressions, as they relate to Phytopharm,
are intended to identify forward-looking statements.  By their nature, forward-
looking statements involve risk and uncertainty because they reflect
Phytopharm's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  There is no guarantee that the
expected events, trends or results will actually occur.  Any changes in such
assumptions or expectations could cause actual results to differ materially from
current expectations./


                      This information is provided by RNS
            The company news service from the London Stock Exchange